Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CeCART-19
- Development stage
- Preclinical
- Lead developer
- Innovative Cellular Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CeCART-19 is a chimeric antigen receptor (CAR) T-cell therapy targeting CD19, designed for the treatment of CD19-positive hematologic malignancies. It consists of autologous T cells that have been genetically modified to express a CAR targeting the CD19 antigen on the surface of malignant B cells. The primary mechanism involves redirection of T cell cytotoxicity against CD19-expressing tumor cells. CeCART-19 is primarily used in B-cell cancers such as certain leukemias and lymphomas. The specific molecular structure or co-stimulatory domains of CeCART-19 are not detailed in currently available public sources, but the nomenclature and design are consistent with other clinical CD19 CAR-T cell therapies.
- Brand names
- CeCART-19CeCART19CeCART 19
- Other names
- CeCART-19CeCART19CeCART 19
02
Targets
Beyond the preview
Go deeper on CeCART-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CeCART-19.